289 related articles for article (PubMed ID: 23641043)
1. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
2. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
[TBL] [Abstract][Full Text] [Related]
3. Cancer of unknown primary site: evolving understanding and management of patients.
Greco FA
Clin Adv Hematol Oncol; 2012 Aug; 10(8):518-24. PubMed ID: 23073050
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
5. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
6. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
8. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
Varadhachary G
Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
Horlings HM; van Laar RK; Kerst JM; Helgason HH; Wesseling J; van der Hoeven JJ; Warmoes MO; Floore A; Witteveen A; Lahti-Domenici J; Glas AM; Van't Veer LJ; de Jong D
J Clin Oncol; 2008 Sep; 26(27):4435-41. PubMed ID: 18802156
[TBL] [Abstract][Full Text] [Related]
10. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
Dennis JL; Hvidsten TR; Wit EC; Komorowski J; Bell AK; Downie I; Mooney J; Verbeke C; Bellamy C; Keith WN; Oien KA
Clin Cancer Res; 2005 May; 11(10):3766-72. PubMed ID: 15897574
[TBL] [Abstract][Full Text] [Related]
11. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.
Handorf CR; Kulkarni A; Grenert JP; Weiss LM; Rogers WM; Kim OS; Monzon FA; Halks-Miller M; Anderson GG; Walker MG; Pillai R; Henner WD
Am J Surg Pathol; 2013 Jul; 37(7):1067-75. PubMed ID: 23648464
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
Hainsworth JD; Greco FA
Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
[TBL] [Abstract][Full Text] [Related]
13. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.
Kulkarni A; Pillai R; Ezekiel AM; Henner WD; Handorf CR
Diagn Pathol; 2012 Aug; 7():110. PubMed ID: 22909314
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.
Greco FA; Spigel DR; Yardley DA; Erlander MG; Ma XJ; Hainsworth JD
Oncologist; 2010; 15(5):500-6. PubMed ID: 20427384
[TBL] [Abstract][Full Text] [Related]
15. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
Greco FA; Hainsworth JD
Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
[TBL] [Abstract][Full Text] [Related]
16. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI.
Gross-Goupil M; Massard C; Lesimple T; Merrouche Y; Blot E; Loriot Y; Mathieu MC; Fizazi K
Onkologie; 2012; 35(1-2):54-5. PubMed ID: 22310348
[No Abstract] [Full Text] [Related]
17. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
[TBL] [Abstract][Full Text] [Related]
18. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
19. Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.
Staub E; Buhr HJ; Gröne J
Oncogene; 2010 Aug; 29(31):4485-92. PubMed ID: 20514016
[TBL] [Abstract][Full Text] [Related]
20. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay.
Stancel GA; Coffey D; Alvarez K; Halks-Miller M; Lal A; Mody D; Koen T; Fairley T; Monzon FA
Cancer Cytopathol; 2012 Feb; 120(1):62-70. PubMed ID: 21717591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
